Codex DNA in Strategic, Licensing Deal With Pfizer
January 10 2022 - 7:37AM
Dow Jones News
By Chris Wack
Codex DNA Inc. said it entered a strategic collaboration and
licensing agreement with Pfizer Inc. to access and further develop
Codex DNA's novel EDS technology for potential application by
Pfizer for its mRNA-based vaccines and other biopharma
products.
The company said the financial terms of the deal include an
upfront payment from Pfizer to Codex DNA, along with success-based
technical milestone payments that could be earned in the near
term.
Codex DNA also is eligible to receive additional milestone
payments based on the achievement of specified development,
regulatory and commercialization goals associated with any products
developed from the application of Codex DNA's technology developed
and licensed under the agreement.
Under this agreement, Pfizer gains early access to custom,
state-of-the-art Codex DNA technology, including use of its
proprietary short oligo ligation assembly SOLA EDS technology.
Codex DNA said it will continue to offer its catalog of
synthetic genomes, including SARS-CoV-2, for research use for
discovering monoclonal antibody treatments, small-molecule
therapies, diagnostic assays, and new vaccines against specific
variants.
Codex DNA shares were up 26% to $11.85 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 10, 2022 07:22 ET (12:22 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Oct 2024 to Nov 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Nov 2023 to Nov 2024
